aibioIntellia plans about 27% net workforce cut, drops NTLA-3001, ends 2024 with $862 million
Tickers NTLA
Intellia says it is cutting its workforce by about 27% net in 2025 and dropping NTLA-3001 to focus on NTLA-2002 and nex-z. It ended 2024 with approximately $862 million and expects about $8 million in charges, but the release gives no headcount or savings figure.
Key facts
- Company
- Intellia Therapeutics, Inc. (NASDAQ: NTLA)
- News type
- Distress
- Primary source
- Intellia Therapeutics, Inc. 8-K (2025-01-10)
What Intellia announced
Intellia Therapeutics, Inc. (NASDAQ: NTLA) said on January 9, 2025 that it is reorganizing to concentrate on two late-stage gene editing programs: NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z), formerly known as NTLA-2001, for transthyretin (ATTR) amyloidosis. The company discontinued development of NTLA-3001, which was aimed at alpha-1 antitrypsin deficiency-associated lung disease, along with select research-stage programs. The announcement was a press release filed as an exhibit to a Form 8-K on January 10, 2025.
Over the course of 2025, the reorganization will result in a net workforce reduction of approximately 27%. The release does not say how many employees that covers or how large the gross reduction is. The company expects to incur charges of approximately $8 million associated with the reorganization, anticipated in the first quarter of 2025.
Chief Executive Officer John Leonard, M.D. said the company has "made a difficult decision to focus our resources predominantly on NTLA-2002 and nex-z". The release gives no data on NTLA-3001 and does not say how much had been spent on it.
Cash and runway
Intellia ended the fourth quarter of 2024 with approximately $862 million in cash, cash equivalents and investments. The company says the combination of that cash and the anticipated cost savings is expected to provide cash runway into the first half of 2027. It gives no dollar figure for the savings, no net loss for 2024 and no quarterly cash use, so a reader cannot test the runway claim from the release alone.
A change at the top of research
Laura Sepp-Lorenzino, Ph.D., the chief scientific officer, announced her retirement effective December 31, 2025, after more than 30 years in the biopharmaceutical industry and academia. She will move out of the chief scientific officer role and continue as a Senior Scientific Advisor for the rest of the year.
Birgit Schultes, Ph.D., who has led Immunology and Cell Therapy since 2017, will be promoted to Executive Vice President and Chief Scientific Officer effective January 13, 2025. The release says she has over 20 years of experience in drug development and biotechnology, including the clinical development of cell therapies and complex biologic products.
The two priority programs
For NTLA-2002, patients are enrolling in the pivotal Phase 3 HAELO study. The release lists dosing the first patient in HAELO in the first quarter of 2025 as a milestone, although it also says patients are actively enrolling. Intellia plans to complete enrollment in the second half of 2025 and to submit a Biologics License Application in the second half of 2026. The company points to Phase 2 data presented in October 2024 at the American College of Allergy, Asthma & Immunology meeting, which it says showed the potential to end chronic prophylaxis treatment and provide freedom from attacks after a one-time infusion. That is Phase 2 evidence, and the Phase 3 study uses the 50 mg dose.
For nex-z, the Phase 3 MAGNITUDE study in ATTR amyloidosis with cardiomyopathy is, the company says, tracking ahead of its target enrollment. Intellia expects more than 550 patients enrolled by year end. Patients with hereditary ATTR with polyneuropathy are screening for the Phase 3 MAGNITUDE-2 study. At the American Heart Association meeting in November 2024, the company presented what it called the first clinical evidence that reductions in serum TTR after one treatment "may halt, and potentially reverse, disease progression". The wording is hedged, and the pivotal studies have not reported. The release mentions Regeneron Pharmaceuticals, Inc. only in its forward-looking statements, as co-developer of the ATTR program.
Commercial plans
Intellia describes an evolution from a late-stage development company to a commercial-ready organization by the end of 2026. Its stated steps are completing the commercial leadership team by the second half of 2025, expanding medical education in HAE and ATTR amyloidosis, and starting pre-approval information exchange so payers can plan for coverage and formulary decisions. The release's forward-looking statements give the leadership buildout as the first half of 2025, which does not match the second half stated in the priorities section.